voyager therapeutics stock forecast

• Today's news
• Reviews and deals
• Climate change
• 2024 election
• Fall allergies
• Health news
• Mental health
• Sexual health
• Family health
• So mini ways
• Unapologetically
• Buying guides

Entertainment

• How to Watch
• My Portfolio
• Latest News
• Stock Market
• Biden Economy
• Stocks: Most Actives
• Stocks: Gainers
• Stocks: Losers
• Trending Tickers
• World Indices
• US Treasury Bonds
• Top Mutual Funds
• Highest Open Interest
• Highest Implied Volatility
• Stock Comparison
• Advanced Charts
• Currency Converter
• Basic Materials
• Communication Services
• Consumer Cyclical
• Consumer Defensive
• Financial Services
• Industrials
• Real Estate
• Mutual Funds
• Credit Cards
• Balance Transfer Cards
• Cash-back Cards
• Rewards Cards
• Travel Cards
• Student Loans
• Personal Loans
• Car Insurance
• Mortgage Calculator
• Morning Brief
• Market Domination
• Market Domination Overtime
• Asking for a Trend
• Opening Bid
• Stocks in Translation
• Lead This Way
• Good Buy or Goodbye?
• Fantasy football
• Pro Pick 'Em
• College Pick 'Em
• Fantasy baseball
• Fantasy hockey
• Fantasy basketball
• Download the app
• Daily fantasy
• Scores and schedules
• GameChannel
• World Baseball Classic
• Premier League
• CONCACAF League
• Champions League
• Motorsports
• Horse racing
• Newsletters

New on Yahoo

• Privacy Dashboard

Yahoo Finance

Voyager therapeutics, inc. (vygr).

• Previous Close 8.80
• Bid 8.50 x 100
• Ask 8.54 x 100
• Day's Range 8.45 - 8.75
• 52 Week Range 6.06 - 14.07
• Volume 363,600
• Avg. Volume 523,477
• Market Cap (intraday) 462.89M
• Beta (5Y Monthly) 1.04
• PE Ratio (TTM) --
• EPS (TTM) -0.17
• Earnings Date Aug 1, 2024 - Aug 5, 2024
• Forward Dividend & Yield --
• Ex-Dividend Date --
• 1y Target Est 17.56

Voyager Therapeutics, Inc. Overview Biotechnology / Healthcare

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Full Time Employees

December 31

Fiscal Year Ends

Biotechnology

Recent News: VYGR

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

Q1 2024 voyager therapeutics inc earnings call, voyager therapeutics inc (vygr) q1 2024 earnings call transcript highlights: strategic ....

Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

Voyager Therapeutics' (NASDAQ:VYGR) three-year earnings growth trails the splendid shareholder returns

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates

Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates

Performance overview: vygr.

Trailing total returns as of 6/14/2024, which may include dividends or other distributions. Benchmark is S&P 500 .

1-Year Return

3-year return, 5-year return, compare to: vygr.

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: VYGR

Valuation measures.

Enterprise Value

Trailing P/E

Forward P/E

PEG Ratio (5yr expected)

Price/Sales (ttm)

Price/Book (mrq)

Enterprise Value/Revenue

Enterprise Value/EBITDA

Financial Highlights

Profitability and income statement.

Profit Margin

Return on Assets (ttm)

Return on Equity (ttm)

Revenue (ttm)

Net Income Avi to Common (ttm)

Diluted EPS (ttm)

Balance Sheet and Cash Flow

Total Cash (mrq)

Total Debt/Equity (mrq)

Levered Free Cash Flow (ttm)

Research Analysis: VYGR

Analyst price targets, analyst recommendations.

• Underperform

People Also Watch

• Top Stock Gainers Today
• Top Stock Losers Today
• Top Stock Gainers 1 Week
• Top Stock Losers 1 Week
• Top Stock Gainers 1 Month
• Top Stock Losers 1 Month
• Top Stock Gainers 6 Month
• Top Stock Losers 6 Month
• Penny Stock To Buy Now
• Top OTC Stock Gainers
• S&P 500 (^GSPC) Companies
• Top 100 Popular Stocks on Robinhood in 2023, 2024
• Top Artificial Intelligence Stocks Under $10
• Lithium Stocks List
• Best Dividend Stocks to Buy in 2023
• Most Undervalued Stocks Today
• Most Overvalued Stocks Today
• Most Active Stocks Today
• The Berkshire Hathaway Portfolio
• Top Small Caps Stocks Gainers

Voyager Therapeutics Inc (VYGR)

Voyager therapeutics inc stock (vygr) forecast, is voyager therapeutics inc (vygr) a buy now.

• RSI (Relative Strength Index): The RSI(14) value of 50.63 indicates that VYGR is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
• STOCH (Stochastic Oscillator): The STOCH value of 70.29 indicates that VYGR is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
• STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 65.84 indicates that VYGR is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
• ADX (Average Directional Index): The ADX value of The ADX value of 11.9 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
• CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 37.29 indicates that VYGR is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.

Long-term VYGR price forecast for 2025, 2030, 2035, 2040, 2045 and 2050

Based on our analysis about Voyager Therapeutics Inc financial reports and earnings history, Voyager Therapeutics Inc (VYGR) stock could reach $7.9924 by 2030, $15.23 by 2040 and $47.06 by 2050. See the projected annual prices until 2050 of the Voyager Therapeutics Inc stock below:

• Voyager Therapeutics Inc (VYGR) is expected to reach an average price of $6.1819 in 2035, with a high prediction of $6.6695 and a low estimate of $6.3919. This indicates an $-27.36% rise from the last recorded price of $8.51.
• Voyager Therapeutics Inc (VYGR) stock is projected to chart a bullish course in 2040, with an average price target of $15.94, representing an $87.25% surge from its current level. The forecast ranges from a conservative $15.63 to a sky-high $15.23.
• Our analysts predict Voyager Therapeutics Inc (VYGR) to jump 245.94% by 2045, soaring from $29.72 to an average price of $29.44, potentially reaching $29.38. While $29.72 is the low estimate, the potential upside is significant.
• Voyager Therapeutics Inc (VYGR) stock is expected to climb by 2050, reaching an average of $42.72, a $401.97% jump from its current level. However, a wide range of estimates exists, with high and low targets of $47.06 and $45.00, respectively, highlighting the market's uncertainty.

Voyager Therapeutics Inc Stock (VYGR) Year by Year Forecast

Voyager therapeutics inc stock (vygr) price forecast for 2024, voyager therapeutics inc stock (vygr) price forecast for 2025, voyager therapeutics inc stock (vygr) price forecast for 2026, voyager therapeutics inc stock (vygr) price forecast for 2027, voyager therapeutics inc stock (vygr) price forecast for 2028, voyager therapeutics inc stock (vygr) price forecast for 2029, voyager therapeutics inc stock (vygr) price forecast for 2030, similar to vygr.

NASDAQ: VYGR Voyager Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for vygr, based on 6 analyst s offering 12 month price targets for voyager therapeutics inc ., should i buy or sell vygr stock, based on 6 analyst s offering ratings for voyager therapeutics inc ., be the first to know when wall street analysts revise their vygr stock forecasts and price targets. get free vygr updates, vygr stock forecasts by analyst, forecast return on equity, is vygr forecast to generate an efficient return, forecast return on assets, is vygr forecast to generate an efficient return on assets, vygr earnings per share forecast, what is vygr 's earnings per share in the next 3 years based on estimates from 5 analyst s , vygr revenue forecast, what is vygr 's revenue in the next 3 years based on estimates from 4 analyst s , vygr revenue growth forecast, how is vygr forecast to perform vs biotechnology companies and vs the us market, vygr vs biotech stocks, voyager therapeutics stock forecast faq.

Is Voyager Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

What is VYGR's earnings growth forecast for 2024-2026?

What is VYGR's revenue growth forecast for 2024-2026?

What is VYGR's forecast return on assets (ROA) for 2024-2027?

What is VYGR's Price Target?

What is VYGR's Earnings Per Share (EPS) forecast for 2024-2026?

What is VYGR's forecast return on equity (ROE) for 2024-2027?

Stock Tools

Stock ideas.

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Voyager Therapeutics Inc

Ever heard of finviz*elite.

Our premium service offers you real-time quotes, advanced visualizations, technical studies, and much more. Become Elite and make informed financial decisions.

Upgrade your FINVIZ experience

Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.

We couldn’t find any results matching your search.

Please try using other words for your search or explore other sections of the website for relevant information.

We’re sorry, we are currently experiencing some issues, please try again later.

Our team is working diligently to resolve the issue. Thank you for your patience and understanding.

Bid Price and Ask Price

The  bid  &  ask  refers to the price that an investor is willing to buy or sell a stock. The bid is the highest amount that a buyer is currently willing to pay, whereas the ask is the lowest amount that a seller is currently willing to sell. The numbers next to the bid/ask are the “ size ”. The bid size displays the total amount of desired shares ... Read More. to buy at that price, and the ask size is the number of shares offered for sale at that price. The data displayed in the quote bar updates every 3 seconds; allowing you to monitor prices in real-time. The  bid-ask spread  can indicate a stock’s liquidity, which is how easy it is to buy and sell in the marketplace. Often, a smaller spread suggests higher liquidity, meaning more buyers and sellers in the market are willing to negotiate. In contrast, a larger spread suggests lower liquidity, as there are fewer investors willing to negotiate. You can use the bid-ask spread to determine whether to place a  market order  or  limit order  when trading, helping you to optimize your price and have a successful order execution. Real-time bid and ask information is powered by Nasdaq Basic, a premier market data solution. This data feed is available via Nasdaq Data Link APIs; to learn more about subscribing, visit  Nasdaq Data Link's products page . ... Read Less.

• After-Hours
• Press Releases
• Analyst Research
• Dividend History
• Historical Quotes
• Historical NOCP
• P/E & PEG Ratios
• Option Chain
• Short Interest
• Institutional Holdings
• Insider Activity
• SEC Filings
• Revenue EPS

Symbol Search

Recently viewed.

Analyze your stocks, your way

Leverage the Nasdaq+ Scorecard to analyze stocks based on your investment priorities and our market data.

Latest News

This data feed is not available at this time.

Trending Stocks

Trending etfs, trending indexes.

• Real-time Data is provided using Nasdaq Last Sale Data

Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Register for your free account today at  data.nasdaq.com .

• Type a symbol or company name. When the symbol you want to add appears, add it to My Quotes by selecting it and pressing Enter/Return.

These symbols will be available throughout the site during your session.

Your symbols have been updated

Edit watchlist.

• Type a symbol or company name. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return.

Opt in to Smart Portfolio

Smart Portfolio is supported by our partner TipRanks. By connecting my portfolio to TipRanks Smart Portfolio I agree to their Terms of Use .

Voyager Therapeutics, Inc.

NasdaqGS:VYGR Stock Report

Market Cap: US$478.7m

Voyager Therapeutics Future Growth

Future criteria checks 0/6.

Voyager Therapeutics's revenue and earnings are forecast to decline at 5.2% and 21.8% per annum respectively. EPS is expected to decline by 9.6% per annum. Return on equity is forecast to be -34.6% in 3 years.

Key information

Earnings growth rate

EPS growth rate

Recent future growth updates

Consensus revenue estimates increase by 29%, consensus revenue estimates fall by 21%, price target increased by 9.8% to us$11.17, price target increased to us$8.20, consensus revenue estimates increase by 170%, consensus forecasts updated, recent updates, voyager therapeutics, inc. appoints nathan jorgensen as chief financial officer, effective july 8, 2024, voyager: alzheimer's clinical trial start (vy-tau01) strengthens investment thesis, voyager therapeutics, inc announces first participants dosed in single ascending dose trial of vy-tau01 for the treatment of alzheimer’s disease, first quarter 2024 earnings: eps and revenues exceed analyst expectations, voyager therapeutics, inc. presents data for second-generation, tracer™-generated capsids and cns gene therapy programs advancing toward clinical trials at the asgct 27th annual meeting, voyager therapeutics, inc. to report q1, 2024 results on may 13, 2024, investor sentiment improves as stock rises 16%, voyager therapeutics, inc., annual general meeting, jun 05, 2024, president recently sold us$119k worth of stock, president notifies of intention to sell stock, voyager therapeutics, inc. announces appointment of toby ferguson as chief medical officer, effective march 25, 2024, there's no escaping voyager therapeutics, inc.'s (nasdaq:vygr) muted revenues despite a 28% share price rise.

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

What does the future hold for voyager therapeutics, inc. (nasdaq:vygr) these analysts have been cutting their estimates.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Voyager therapeutics, inc. announces selection of gene therapy development candidate for friedreich's ataxia in collaboration with neurocrine biosciences, triggering milestone payment, investor sentiment improves as stock rises 18%, president recently sold us$97k worth of stock, voyager therapeutics, inc. to report q4, 2023 results on feb 28, 2024, voyager therapeutics reports robust preclinical activity in tau silencing gene therapy program for alzheimer's disease and advances program into late research, new minor risk - share price stability, voyager therapeutics, inc. has filed a follow-on equity offering in the amount of $100 million., voyager therapeutics, inc. has completed a follow-on equity offering in the amount of $100 million., voyager therapeutics, inc. (nasdaq:vygr) surges 45% yet its low p/s is no reason for excitement.

Voyager Therapeutics, Inc. Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

Third quarter 2023 earnings: eps in line with analyst expectations despite revenue beat, voyager therapeutics, inc. to report q3, 2023 results on nov 06, 2023, chief financial officer recently sold us$95k worth of stock, chief financial officer notifies of intention to sell stock, chief scientific officer notifies of intention to sell stock, new major risk - revenue and earnings growth, second quarter 2023 earnings: eps and revenues exceed analyst expectations, voyager therapeutics, inc. to report q2, 2023 results on aug 03, 2023, voyager therapeutics announces appointment of jacquelyn fahey sandell as chief legal officer, chief science officer notifies of intention to sell stock, investor sentiment deteriorates as stock falls 16%, investor sentiment improves as stock rises 25%, voyager therapeutics, inc. appoints george scangos as director and as member of science and technology committee, first quarter 2023 earnings: eps and revenues exceed analyst expectations, president recently sold us$58k worth of stock, chief operating officer recently sold us$126k worth of stock, full year 2022 earnings: eps and revenues miss analyst expectations, voyager therapeutics, inc. appoints grace e. colón, ph.d., to its board of directors, effective on january 1, 2023, third quarter 2022 earnings: eps and revenues exceed analyst expectations, voyager therapeutics, inc. to report q3, 2022 results on nov 08, 2022, voyager therapeutics, inc presents data characterizing a novel cns receptor and demonstrating the low-dose potential of tracer™ generated capsid families, voyager stock rises as pfizer opts to use aav capsid for neurologic disease target, voyager therapeutics appoints peter pfreundschuh as cfo, effective september 19, 2022, voyager therapeutics hires new finance chief, consensus revenue estimates fall by 86%, second quarter 2022 earnings released: us$0.50 loss per share (vs us$0.80 loss in 2q 2021), voyager therapeutics gaap eps of -$0.50 misses by $0.02, voyager therapeutics presents new data demonstrating novel candidate therapeutic antibodies reduced tau pathology in multiple preclinical models, voyager therapeutics, inc. to report q2, 2022 results on aug 04, 2022, voyager therapeutics appoints catherine j. mackey, ph.d. to its board of directors, voyager therapeutics, inc. announces executive changes, looking back in on voyager therapeutics, voyager therapeutics, inc. to present new preclinical data on family of aav9-derived tracer capsids demonstrating cross-species central nervous system (cns) transduction, voyager therapeutics, inc. to present preclinical data from its vectorized anti-her2 antibody program and a novel aav5-derived tracer™ capsid at the 25th american society of gene and cell therapy annual meeting, need to know: analysts just made a substantial cut to their voyager therapeutics, inc. (nasdaq:vygr) estimates.

Consensus revenue estimates fall by 37%

First quarter 2022 earnings: eps and revenues miss analyst expectations, price target increased to us$6.80, voyager therapeutics, inc., annual general meeting, jun 06, 2022, mark levin and steven paul requests voyager therapeutics not to nominate for re-election to the board, voyager does a reboot after first generation failures, consensus revenue estimates increase by 87%, full year 2021 earnings: revenues exceed analysts expectations while eps lags behind, companies like voyager therapeutics (nasdaq:vygr) could be quite risky.

Voyager Therapeutics, Inc. Announces Executive Appointments

Price target decreased to us$6.00, voyager therapeutics: another year, another deal, third quarter 2021 earnings released: us$0.67 loss per share (vs us$2.30 profit in 3q 2020), investor sentiment deteriorated over the past week, price target increased to us$7.07, investor sentiment improved over the past week, some analysts just cut their voyager therapeutics, inc. (nasdaq:vygr) estimates.

Second quarter 2021 earnings released: US$0.80 loss per share (vs US$0.23 loss in 2Q 2020)

Price target increased to us$10.31, newsflash: voyager therapeutics, inc. (nasdaq:vygr) analysts have been trimming their revenue forecasts.

Consensus revenue estimates fall to US$17.5m

Earnings and revenue growth forecasts, analyst future growth forecasts.

Earnings vs Savings Rate : VYGR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market : VYGR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings : VYGR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market : VYGR's revenue is expected to decline over the next 3 years (-5.2% per year).

High Growth Revenue : VYGR's revenue is forecast to decline over the next 3 years (-5.2% per year).

Earnings per Share Growth Forecasts

Future return on equity.

Future ROE : VYGR is forecast to be unprofitable in 3 years.

Discover growth companies

High growth companies in the Pharmaceuticals-biotech industry.

Voyager Therapeutics (VYGR) Stock Price & Analysis

Vygr stock chart & stats, voyager therapeutics news.

Options Prices

Ownership overview, risk analysis, website traffic, voyager therapeutics stock smart score, analyst consensus, blogger sentiment, hedge fund trend, insider transactions, crowd wisdom, news sentiment, fundamentals, company description, voyager therapeutics, vygr earnings call, vygr stock 12 month forecast, average price target, technical analysis, best analysts covering vygr, get more with tipranks premium.

• My View My View
• Following Following
• Saved Saved

trading lower

trading higher

Voyager Therapeutics Inc

Key statistics.

1.70 mean rating - 10 analysts

2024 (millions USD)

About Voyager Therapeutics Inc (VYGR.OQ)

Company information.

Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.

Contact Information

+ 1 ( 857 ) 2595340

https://www.voyagertherapeutics.com/

Biotechnology & Drugs

Executive Leadership

Income statement.

2023 (millions USD)

Balance Sheet

Source: LSEG New Tab , opens new tab - data delayed by at least 15 minutes

Markets Performance

Commodities chevron, currencies chevron, rates & bonds chevron, stocks chevron.

Vision, Mission, & Strategy

Management Team

Board of Directors

Scientific Advisory Board

Core Values

• VY-TAU01 for Alzheimer’s

• Alzheimer’s early research

• SOD1 for ALS

Patient Resources

Partnerships

TRACER Platform

Non-Viral Delivery

Publications & Presentations

Press Releases

Events & Presentations

Stock Information

Shareholder Services

Job Openings

Our Community

Mission & Values

Disclosures

Release Details

Voyager therapeutics to present at multiple virtual investor conferences.

LEXINGTON, Mass. , June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, 2024 , at 1:35 p.m. ET and at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 , at 7:00 a.m. ET .

Webcasts of the presentations may be accessed from the Investors section of Voyager’s website at ir.voyagertherapeutics.com . A replay of the webcasts will be archived on the Company's website for at least 30 days.

About Voyager Therapeutics Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG ; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com .

Voyager Therapeutics ® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Brooke Shenkin , [email protected]

Source: Voyager Therapeutics, Inc.

• Voyager Therapeutics-stock
• News for Voyager Therapeutics

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings to Voyager a breadth of experience spanning investment banking, public and private healthcare investing, sell-side research, and operational roles in biotech, as well as expertise in neuroscience. He most recently served as Chief Financial Officer for Vor Biopharma Inc.

“Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurotherapeutics based on genetically-validated targets,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “Nathan’s highly differentiated background integrates operational and strategic leadership, a deep understanding of value creation in the life sciences, and expertise in neuroscience, which will be critical as we advance additional programs into the clinic and build a multi-modality neurotherapeutics company.”

As CFO at Vor Bio, Jorgensen oversaw finance, communications, facilities, GMP, and IT and raised over $400 million in public and private financings. Prior to this, he managed global public and private healthcare investing, including in early-stage biotech companies, for the Qatar Investment Authority, the sovereign wealth fund of the State of Qatar. Previously, Jorgensen led pharma and biotech investing efforts on the all-cap equity healthcare team at Calamos Investments LLC, a diversified global investment firm. Before joining Calamos, he covered mid- and large-cap biotech companies as an equity research analyst at Stifel, Nicolaus & Company, Incorporated. Prior to entering the financial sector, Jorgensen investigated the pathobiology of Parkinson’s disease as a postdoctoral scientist at the Columbia University Irving Medical Center. He received his MBA from the Cornell SC Johnson College of Business, his Ph.D. in neuroscience from the University of Minnesota, and his B.A. from St. John’s University.

“Voyager is advancing a suite of transformative neurogenetic medicines, with multiple opportunities to create value for patients and for shareholders,” said Jorgensen. “I am excited about the possibilities offered by Voyager’s differentiated platform, along with its unparalleled team in the field of neuroscience. The pipeline is poised to tackle the delivery hurdles that have held back progress in neurology, and I look forward to applying my strategic financial expertise to enable the team to execute and deliver on the promise of its tremendous science.”

About Voyager Therapeutics Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com.

Voyager Therapeutics ® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Forward-Looking Statements This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “potential,” “anticipate,” “expect,” “will,” “may,” and other similar expressions are intended to identify forward-looking statements.

For example, all statements Voyager makes regarding the timing and effective date of the appointment of Dr. Jorgensen, the contributions Dr. Jorgensen may make in his role with the Company, and Voyager’s ability to advance additional programs into the clinic and build a multi-modality neurotherapeutics company are forward looking.

All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the continued development of Voyager’s technology platforms, including Voyager’s TRACER platform and its antibody screening technology; the ability to initiate and conduct preclinical studies in animal models; the development by third parties of capsid identification platforms that may be competitive to Voyager’s TRACER capsid discovery platform; Voyager’s ability to create and protect intellectual property rights associated with the TRACER capsid discovery platform, the capsids identified by the platform, and development candidates for Voyager’s pipeline programs; the initiation, timing, conduct and outcomes of Voyager’s preclinical and clinical studies; the possibility or the timing of Voyager’s receipt of program reimbursement, development or commercialization milestones, option exercise, and other payments under Voyager’s existing licensing or collaboration agreements; the ability of Voyager to negotiate and complete licensing or collaboration agreements with other parties on terms acceptable to Voyager and the third parties; the ability to attract and retain talented directors, employees, and contractors; and the sufficiency of cash resources to fund its operations and pursue its corporate objectives.

These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Contacts Trista Morrison, NACD.DC, [email protected] Investors: Adam Bero, Ph.D., [email protected] Media: Brooke Shenkin, [email protected]

Voyager Therapeutics News MORE

Related stocks.

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here . By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service .

Member Sign In

Don't Know Your Password?

• Zacks #1 Rank
• Zacks Industry Rank
• Zacks Sector Rank
• Equity Research
• Mutual Funds
• Mutual Fund Screener
• ETF Screener
• Earnings Calendar
• Earnings Releases
• Earnings ESP
• Earnings ESP Filter
• Stock Screener
• Premium Screens
• Basic Screens
• Thematic Screens
• Research Wizard
• Personal Finance
• Money Management
• Retirement Planning
• Tax Information
• My Portfolio
• Create Portfolio
• Style Scores
• Testimonials
• Zacks.com Tutorial

Services Overview

• Zacks Ultimate
• Zacks Investor Collection
• Zacks Premium

Investor Services

• ETF Investor
• Home Run Investor
• Income Investor
• Stocks Under $10
• Value Investor
• Top 10 Stocks

Other Services

• Method for Trading
• Zacks Confidential

Trading Services

• Black Box Trader
• Counterstrike
• Headline Trader
• Insider Trader
• Large-Cap Trader
• Options Trader
• Short Sell List
• Surprise Trader
• Alternative Energy

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK . If you do not, click Cancel.

Voyager Therapeutics (VYGR)

(delayed data from nsdq).

-0.29 (-3.30%)

Updated Jun 14, 2024 04:00 PM ET

After-Market: $8.52 +0.01 (0.12%) 7:58 PM ET

Add to portfolio

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B  Value | C  Growth | C  Momentum | B  VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Voyager Therapeutics (VYGR) Price Targets

Price target.

Based on short-term price targets offered by nine analysts, the average price target for Voyager Therapeutics comes to $17.56. The forecasts range from a low of $8.00 to a high of $30.00. The average price target represents an increase of 99.55% from the last closing price of $8.80.

Analyst Price Targets (9 )

Broker rating.

Voyager Therapeutics currently has an average brokerage recommendation (ABR) of 1.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.20 a month ago based on 10 recommendations.

Of the 10 recommendations deriving the current ABR, nine are Strong Buy, representing 90% of all recommendations. A month ago, Strong Buy represented 90%.

Broker Rating Breakdown

Brokerage Recommendations

1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.

2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.

Analyst Upgrades/Downgrades

Average brokerage rating.

This file is used for Yahoo remarketing pixel add

Due to inactivity, you will be signed out in approximately:

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

“Voyager has built a strong financial position from which to advance our clinical-stage and emerging pipeline of neurotherapeutics based on genetically-validated targets,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager. “Nathan’s highly differentiated background integrates operational and strategic leadership, a deep understanding of value creation in the life sciences, and expertise in neuroscience, which will be critical as we advance additional programs into the clinic and build a multi-modality neurotherapeutics company.”

As CFO at Vor Bio, Jorgensen oversaw finance, communications, facilities, GMP, and IT and raised over $400 million in public and private financings. Prior to this, he managed global public and private healthcare investing, including in early-stage biotech companies, for the Qatar Investment Authority, the sovereign wealth fund of the State of Qatar. Previously, Jorgensen led pharma and biotech investing efforts on the all-cap equity healthcare team at Calamos Investments LLC, a diversified global investment firm. Before joining Calamos, he covered mid- and large-cap biotech companies as an equity research analyst at Stifel, Nicolaus & Company, Incorporated. Prior to entering the financial sector, Jorgensen investigated the pathobiology of Parkinson’s disease as a postdoctoral scientist at the Columbia University Irving Medical Center. He received his MBA from the Cornell SC Johnson College of Business, his Ph.D. in neuroscience from the University of Minnesota, and his B.A. from St. John’s University.

“Voyager is advancing a suite of transformative neurogenetic medicines, with multiple opportunities to create value for patients and for shareholders,” said Jorgensen. “I am excited about the possibilities offered by Voyager’s differentiated platform, along with its unparalleled team in the field of neuroscience. The pipeline is poised to tackle the delivery hurdles that have held back progress in neurology, and I look forward to applying my strategic financial expertise to enable the team to execute and deliver on the promise of its tremendous science.”

About Voyager Therapeutics

Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “potential,” “anticipate,” “expect,” “will,” “may,” and other similar expressions are intended to identify forward-looking statements.

For example, all statements Voyager makes regarding the timing and effective date of the appointment of Dr. Jorgensen, the contributions Dr. Jorgensen may make in his role with the Company, and Voyager’s ability to advance additional programs into the clinic and build a multi-modality neurotherapeutics company are forward looking.

All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the continued development of Voyager’s technology platforms, including Voyager’s TRACER platform and its antibody screening technology; the ability to initiate and conduct preclinical studies in animal models; the development by third parties of capsid identification platforms that may be competitive to Voyager’s TRACER capsid discovery platform; Voyager’s ability to create and protect intellectual property rights associated with the TRACER capsid discovery platform, the capsids identified by the platform, and development candidates for Voyager’s pipeline programs; the initiation, timing, conduct and outcomes of Voyager’s preclinical and clinical studies; the possibility or the timing of Voyager’s receipt of program reimbursement, development or commercialization milestones, option exercise, and other payments under Voyager’s existing licensing or collaboration agreements; the ability of Voyager to negotiate and complete licensing or collaboration agreements with other parties on terms acceptable to Voyager and the third parties; the ability to attract and retain talented directors, employees, and contractors; and the sufficiency of cash resources to fund its operations and pursue its corporate objectives.

These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Trista Morrison, NACD.DC, [email protected]

Investors: Adam Bero, Ph.D., [email protected]

Media: Brooke Shenkin, [email protected]